In this Review:
Optimal criteria for successful TKI discontinuation
Management of APLAs and a single thromboembolic event
Ongoing and future therapies in Hodgkin lymphoma
Lymphoid malignancies: new strategies and new therapies
No major negative impact of advanced age with allograft
Assessing allogeneic transplantation for myelofibrosis
Elotuzumab + lenalidomide/ dexamethasone in advanced myeloma
Please login below to download this issue (PDF)